A detailed history of Continuum Advisory, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 33 shares of NBIX stock, worth $4,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33
Previous 23 43.48%
Holding current value
$4,068
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$114.58 - $153.15 $1,145 - $1,531
10 Added 43.48%
33 $3,000
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $2,999 - $3,306
23 New
23 $3,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Continuum Advisory, LLC Portfolio

Follow Continuum Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Continuum Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Continuum Advisory, LLC with notifications on news.